Search

Search Constraints

You searched for: Author/Creator Rulli, Eliana

Search Results

1. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. (June 2017)

2. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

3. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

4. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

5. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

6. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

7. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Issue 2 (17th November 2020)

8. Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres. Issue 8 (7th April 2021)

10. Corrigendum to "Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)" [Eur J Canc 137 (2020). Pages 30–39]. (November 2020)